2-chloro-3--deoxyadenosine and Leukemia--Prolymphocytic

2-chloro-3--deoxyadenosine has been researched along with Leukemia--Prolymphocytic* in 1 studies

Other Studies

1 other study(ies) available for 2-chloro-3--deoxyadenosine and Leukemia--Prolymphocytic

Article	Year
Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues. Leukemia & lymphoma, 1994, Volume: 14, Issue:1-2 This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+, CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical complete remission and a molecular genetic partial remission that has been durable for > 15 months. The other patient had CD4+ T-prolymphocytic leukemia and was unresponsive to both fludarabine and 2-chlorodeoxyadenosine. Further trials of these agents are warranted in T-CLL, especially the LGL variant. Topics: 2-Chloroadenosine; Anemia; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclophosphamide; Deoxyadenosines; Fatal Outcome; Female; Humans; Immunophenotyping; Leukemia, Prolymphocytic; Leukemia, Prolymphocytic, T-Cell; Male; Methotrexate; Middle Aged; Neoplastic Stem Cells; Prednisone; Salvage Therapy; Vidarabine; Vincristine; Zidovudine	1994

Article

Year

Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.

Leukemia & lymphoma, 1994, Volume: 14, Issue:1-2

This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+, CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical complete remission and a molecular genetic partial remission that has been durable for > 15 months. The other patient had CD4+ T-prolymphocytic leukemia and was unresponsive to both fludarabine and 2-chlorodeoxyadenosine. Further trials of these agents are warranted in T-CLL, especially the LGL variant.

Topics: 2-Chloroadenosine; Anemia; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclophosphamide; Deoxyadenosines; Fatal Outcome; Female; Humans; Immunophenotyping; Leukemia, Prolymphocytic; Leukemia, Prolymphocytic, T-Cell; Male; Methotrexate; Middle Aged; Neoplastic Stem Cells; Prednisone; Salvage Therapy; Vidarabine; Vincristine; Zidovudine

1994